79
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and depletes CD20+ B lymphocytes.

          Related collections

          Author and article information

          Journal
          N Engl J Med
          The New England journal of medicine
          Massachusetts Medical Society
          1533-4406
          0028-4793
          Feb 14 2008
          : 358
          : 7
          Affiliations
          [1 ] Department of Neurology, University of California at San Francisco, San Francisco, CA 94143-0114, USA. hausers@neurology.ucsf.edu
          Article
          358/7/676
          10.1056/NEJMoa0706383
          18272891
          814e410f-c22e-47fd-afb6-91082c0fcc33
          Copyright 2008 Massachusetts Medical Society.
          History

          Comments

          Comment on this article